Future Market Insights23h
Cell Therapy Manufacturing Industry to Reach USD 15,634.67 Million by 2033, Growing at a 14.2% CAGR
The global cell therapy manufacturing industry is poised for rapid growth, with a projected valuation of USD 4,134.48 million ...
pharmaphorum1h
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...
Breaking Down Legend Biotech: 9 Analysts Share Their Views
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.0, a high estimate of $86.00, ...
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...
Nkarta, Inc.: Trying To Find Space In A Crowded Place
Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple ...
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...
Vittoria Biotherapeutics begins human testing of experimental cell therapy cancer treatment
A Philadelphia cell therapy developer has initiated its first human testing of a potential cancer treatment. Vittoria ...
NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans
NLS Pharmaceutics ( (NLSP) ) has issued an announcement.
NLS Pharmaceutics Shares Rise More Than 50% on Merger Progress
NLS Pharmaceutics shares climbed on Monday after the company took the next step in its proposed merger with Kadimastem. The stock is trading up more than 50% at $2.81. It is down about 30% from Nov. 5 ...